(688796)"BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688796 · · 13 pages · Chinese
Summary by 6ix AI
Key financial highlights include significant increases in revenue and profit compared to the same period last year, driven by growth in pharmacological services and model animal income. The report also outlines the company's commitment to innovation, reflected in a substantial rise in research and development expenditures.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. on 6ix
Earlier from Biocytogen Pharmaceuticals (Beijing)
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Semi-annual Report for 2026
- Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026
- Court Clears Biocytogen’s RenNano® in Landmark Patent Dispute Against Harbour
Follow Biocytogen Pharmaceuticals (Beijing) into a list and get an email when it puts out news.
Follow Biocytogen Pharmaceuticals (Beijing)